ERBB2 and gastric cancer: T-DXd is another anti-HER2 ADC conjugated to a potent topoisomerase 1 inhibitor, that has shown significant and durable efficacy in patients with HER2 positive breast [8, 95] and gastric cancer [96] and has the potential to also improve the outcome of patients with other HER2 positive solid tumors.